Clinical Trials At Southeast Nebraska Cancer Center

Clinical trials are biomedical research studies for patients that follow a pre-defined protocol. The majority of clinical trials at SNCC are interventional studies, meaning patients are assigned to a treatment or other intervention and their outcomes are measured. Southeast Nebraska Cancer Center (SNCC) is approved by the National Cancer Institute (NCI) to offer clinical trials to patients in our community. These promising novel approaches to cancer care offer additional treatment options for patients where opportunities were previously limited.

Cutting-Edge Clinical Trial Access
SNCC is able to offer expanded clinical trial access after becoming members of two major NCI cancer research networks: Alliance as an affiliate of MD Anderson Cancer Center and ECOG-ACRIN. The extensive years-long application process verified that SNCC met all membership requirements including enrollment, data quality, safety and adherence to national policies and procedures.

There are many barriers to cancer patients, especially when it comes to traveling long distances to access clinical trials. With our new NCI-network affiliations, SNCC is now able to offer a spectrum of clinical trials to our patients close to home.  Please see below for open clinical trials.

BREAST CANCER

NRG-BR004 – HER-2 Positive Metastatic Breast Cancer – A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer

EA1131 – Triple-Negative Basal-Like Breast Cancer – Platinum-Based Chemotherapy or Capecitabine in Treating Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

EA1181 – HER-2 positive Stage II-IIIa Breast Cancer – CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy

HEMATOLOGIC CANCER

CONNECT MDS/AML – The Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

PERSPECTIVE – A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naive Subjects with Follicular Lymphoma

SUMMIT – Treatment Patterns, Outcomes, and Patient-Reported Health-Related Quality of Life:  A Prospective Disease Registry of Patients with Mantle Cell Lymphoma Treated with Novel Agents

GASTROINTESTINAL CANCER

A221805 – Stage II-III Colon Cancer Receiving Oxaliplatin – Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study

MK7339-003 (LYNK-003) – Metastatic Colorectal Cancer, 1ST line FOLFOX + Avastin – A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)

EA2186 (GIANT) – 1ST line Metastatic Pancreatic – A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)

THORACIC CANCER

ON HOLD- INTR@PID – mNSCLC, 1ST Line, PD-L1+ – A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-Line Treatment in Patients with PD-L1 Expressing Advanced Non-small Cell Lung Cancer

GX41563 (mNSCLC or ES-SCLC) –  A Multicenter, Low-Interventional Study to Evaluate the Feasibility of a Prospective Clinicogenomic Program

D910LC00001 (MeRmaiD-1) – Stage II-III Resected NSCLC – A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC

PENDING – EA5181 – Unresectable Stage 3 NSCLC – Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

GENITOURINARY

NRG-GU008 (INNOVATE) – Locally Advanced Prostate, Lymph Node Positive – Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy

MK6482-013 – Metastatic clear cell RCC 2ND line and greater (no limit to prior lines of therapy) – Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell

A031704 (PDIGREE) – 1ST line Metastatic clear cell RCC – PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

MK6482-011 – 2ND Line mRCC – Phase 3 Study of MK-6482 in Combination With Lenvatinib Versus Cabozantinib for Second-line Treatment of mRCC

SOLID TUMOR

PENDING – MYTACTIC (ML42439) – Biomarker specific: ROS1, PI3K, ALK, AKT or PTEN loss, TMB High, MSI high, dMMR, ERBB2 – An Open-Label Phase II Study Evaluating Targeted Therapies In Patients Who Have Advanced Solid Tumors With Genomic Alterations Or Protein Expression Patterns Predictive Of Response

  • No Additional Information at This Time.

MK7339-002 (LYNK-002) Previously Treated, HRR/HRD +– A Phase 2 Study of Olaparib Monotherapy in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

TCBIO-001-0710 Biomarker – Caris Biorepository – Solid Tumor Matched Tissue and Blood Collection

INTEGUMENTARY

CASE – CSCC-initiating cemiplimab treatment – Cemiplimab Survivorship Epidemiology Study

S2000: A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases

SURVIVORSHIP

A221602 – Preventing Chemotherapy Induced Nausea and Vomiting (CINV) for Highly Emetogenic Chemotherapy (HEC) regimens – Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

MT Group Biomarker Studies – The list of available biomarker studies is always changing. Please contact SNCC Research for the most current list at genetics@leadingcancercare.com.